Microbial consortia for enhanced and sustainable cannabis production

该提案中所述的研究将产生与大麻产业相关的关键知识，从而能够生产出具有最佳大麻素浓度的高质量植物材料。该项目将解决在大麻生产中使用微生物接种剂方面的三个知识空白：1)商业微生物接种剂微生物质量如何影响植物生长参数、花朵产量和大麻素浓度；2)微生物质量的应用如何通过蛋白质组水平的变化改变大麻类化合物的积累；3)确定微生物接种剂对大麻根的定植如何取决于生长基质和生产系统。这项研究很重要，因为大麻生产者必须能够种植一致的植物材料，同时减少与合成肥投入相关的财务和环境成本。该项目的成果可能是改善大麻生产者的作物生产方法，以增加加拿大合法的大麻供应，使其对大麻生产者、开医用大麻的临床医生和使用医用大麻的患者具有重要意义。大麻生产商将受益于产量的提高和生产成本的降低；临床医生将受益于更广泛的一致的大麻产品，可在治疗各种医疗疾病的临床试验中进行评估；患者将受益于更容易获得一系列以大麻为基础的高质量药物。该项目的预期成果是：更好地了解微生物接种剂如何与大麻植物相互作用，以改善生长、产量和/或大麻素积累。这一知识将为进一步开发用于大麻生产系统的微生物产品铺平道路，该系统在盆栽和水培系统中种植植物。工业合作伙伴微菌质量公司和尤利斯生物技术公司将通过改善对其微生物接种产品影响的机制的了解而受益。加拿大将受益于利用这一知识将自己定位为高质量大麻生产的世界领先者，从而增加大麻销售的税收。

The research described in this proposal will produce critical knowledge relevant for the cannabis industry, allowing for the production of high-quality plant material with optimum cannabinoid concentrations. The project will address three knowledge gaps regarding the use of microbial inoculants in cannabis production: 1) how a commercial microbial inoculant, Miicrobial Mass, affects plant growth parameters, flower yield and cannabinoid concentrations; 2) how the application of Miicrobial Mass alters cannabinoid accumulation through changes at the proteomic level; and 3) determine how cannabis root colonization by microbial inoculants depends on the growing medium and production system. This research is important because cannabis producers must be able to grow consistent plant material while reducing the financial and environmental costs associated with synthetic fertilizer inputs. Outcomes of this project could be improved crop production methods for cannabis producers to increase the legal cannabis supply in Canada, making it important for cannabis producers, clinicians who prescribe medical cannabis and patients that use medical cannabis. Cannabis producers will benefit from improved yield and reduced production costs; clinicians will benefit from a wider range of consistent cannabis products that can be evaluated in clinical trials for treatment of a variety of medical conditions; patients will benefit from improved access to a range of high-quality cannabis-based pharmaceutical products. The anticipated outcomes of this project are: an improved understanding of how microbial inoculants interact with cannabis plants to improve growth, yield and/or cannabinoid accumulation. This knowledge will pave the way for the development of further microbial-based products for use in cannabis production systems that cultivate plants in pots and hydroponic systems. Miicrobial Mass and Ulysse Biotech, the industrial partners, will benefit through improved knowledge of the mechanisms underlying the effects of their microbial inoculant product. Canada will benefit by using this knowledge to position itself as a world leader in production of high-quality cannabis, increased tax revenues from cannabis sales.